Matches in SemOpenAlex for { <https://semopenalex.org/work/W2980134306> ?p ?o ?g. }
- W2980134306 endingPage "1360" @default.
- W2980134306 startingPage "1360" @default.
- W2980134306 abstract "Sprifermin is under investigation as a disease-modifying osteoarthritis drug.To evaluate the effects of sprifermin on changes in total femorotibial joint cartilage thickness in the more symptomatic knee of patients with osteoarthritis.FORWARD (FGF-18 Osteoarthritis Randomized Trial with Administration of Repeated Doses) was a 5-year, dose-finding, multicenter randomized clinical trial conducted at 10 sites. Eligible participants were aged 40 to 85 years with symptomatic, radiographic knee osteoarthritis and Kellgren-Lawrence grade 2 or 3. Enrollment began in July 2013 and ended in May 2014; the last participant visit occurred on May 8, 2017. The primary outcome at 2 years and a follow-up analysis at 3 years are reported.Participants were randomized to 1 of 5 groups: intra-articular injections of 100 μg of sprifermin administered every 6 months (n = 110) or every 12 months (n = 110), 30 μg of sprifermin every 6 months (n = 111) or every 12 months (n = 110), or placebo every 6 months (n = 108). Each treatment consisted of weekly injections over 3 weeks.The primary end point was change in total femorotibial joint cartilage thickness measured by quantitative magnetic resonance imaging at 2 years. The secondary end points (of 15 total) included 2-year change from baseline in total Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) scores. The minimal clinically important difference (MCID) is unknown for the primary outcome; for total WOMAC score in patients with hip and knee osteoarthritis, the absolute MCID is 7 U (95% CI, 4 to 10 U) and the percentage MCID is 14% (95% CI, 9% to 18%).Among 549 participants (median age, 65.0 years; 379 female [69.0%]), 474 (86.3%) completed 2-year follow-up. Compared with placebo, the changes from baseline to 2 years in total femorotibial joint cartilage thickness were 0.05 mm (95% CI, 0.03 to 0.07 mm) for 100 μg of sprifermin administered every 6 months; 0.04 mm (95% CI, 0.02 to 0.06 mm) for 100 μg of sprifermin every 12 months; 0.02 mm (95% CI, -0.01 to 0.04 mm) for 30 μg of sprifermin every 6 months; and 0.01 mm (95% CI, -0.01 to 0.03 mm) for 30 μg of sprifermin every 12 months. Compared with placebo, there were no statistically significant differences in mean absolute change from baseline in total WOMAC scores for 100 μg of sprifermin administered every 6 months or every 12 months, or for 30 μg of sprifermin every 6 months or every 12 months. The most frequently reported treatment-emergent adverse event was arthralgia (placebo: n = 46 [43.0%]; 100 μg of sprifermin administered every 6 months: n = 45 [41.3%]; 100 μg of sprifermin every 12 months: n = 50 [45.0%]; 30 μg of sprifermin every 6 months: n = 40 [36.0%]; and 30 μg of sprifermin every 12 months: n = 48 [44.0%]).Among participants with symptomatic radiographic knee osteoarthritis, the intra-articular administration of 100 μg of sprifermin every 6 or 12 months vs placebo resulted in an improvement in total femorotibial joint cartilage thickness after 2 years that was statistically significant, but of uncertain clinical importance; there was no significant difference for 30 μg of sprifermin every 6 or 12 months vs placebo. Durability of response also was uncertain.ClinicalTrials.gov Identifier: NCT01919164." @default.
- W2980134306 created "2019-10-18" @default.
- W2980134306 creator A5007975327 @default.
- W2980134306 creator A5011776152 @default.
- W2980134306 creator A5025500291 @default.
- W2980134306 creator A5026165132 @default.
- W2980134306 creator A5050872275 @default.
- W2980134306 creator A5051653338 @default.
- W2980134306 creator A5062569126 @default.
- W2980134306 creator A5069018938 @default.
- W2980134306 creator A5088718007 @default.
- W2980134306 creator A5090030145 @default.
- W2980134306 date "2019-10-08" @default.
- W2980134306 modified "2023-10-17" @default.
- W2980134306 title "Effect of Intra-Articular Sprifermin vs Placebo on Femorotibial Joint Cartilage Thickness in Patients With Osteoarthritis" @default.
- W2980134306 cites W1624201580 @default.
- W2980134306 cites W1851925799 @default.
- W2980134306 cites W1937062091 @default.
- W2980134306 cites W1968900840 @default.
- W2980134306 cites W1981923832 @default.
- W2980134306 cites W1992564705 @default.
- W2980134306 cites W1996389266 @default.
- W2980134306 cites W2017638669 @default.
- W2980134306 cites W2024382428 @default.
- W2980134306 cites W2024588402 @default.
- W2980134306 cites W2027970609 @default.
- W2980134306 cites W2068043810 @default.
- W2980134306 cites W2097785638 @default.
- W2980134306 cites W2101679106 @default.
- W2980134306 cites W2106085759 @default.
- W2980134306 cites W2109441608 @default.
- W2980134306 cites W2110143857 @default.
- W2980134306 cites W2140513563 @default.
- W2980134306 cites W2146203940 @default.
- W2980134306 cites W2148857381 @default.
- W2980134306 cites W2167792025 @default.
- W2980134306 cites W2274722622 @default.
- W2980134306 cites W2402307523 @default.
- W2980134306 cites W2481203471 @default.
- W2980134306 cites W2616167388 @default.
- W2980134306 cites W2748169532 @default.
- W2980134306 cites W2748888693 @default.
- W2980134306 cites W2774728583 @default.
- W2980134306 cites W2883617845 @default.
- W2980134306 cites W2892390398 @default.
- W2980134306 cites W4205594235 @default.
- W2980134306 cites W4229985272 @default.
- W2980134306 cites W4231610427 @default.
- W2980134306 cites W4242957258 @default.
- W2980134306 cites W4292528167 @default.
- W2980134306 doi "https://doi.org/10.1001/jama.2019.14735" @default.
- W2980134306 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6784851" @default.
- W2980134306 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31593273" @default.
- W2980134306 hasPublicationYear "2019" @default.
- W2980134306 type Work @default.
- W2980134306 sameAs 2980134306 @default.
- W2980134306 citedByCount "202" @default.
- W2980134306 countsByYear W29801343062019 @default.
- W2980134306 countsByYear W29801343062020 @default.
- W2980134306 countsByYear W29801343062021 @default.
- W2980134306 countsByYear W29801343062022 @default.
- W2980134306 countsByYear W29801343062023 @default.
- W2980134306 crossrefType "journal-article" @default.
- W2980134306 hasAuthorship W2980134306A5007975327 @default.
- W2980134306 hasAuthorship W2980134306A5011776152 @default.
- W2980134306 hasAuthorship W2980134306A5025500291 @default.
- W2980134306 hasAuthorship W2980134306A5026165132 @default.
- W2980134306 hasAuthorship W2980134306A5050872275 @default.
- W2980134306 hasAuthorship W2980134306A5051653338 @default.
- W2980134306 hasAuthorship W2980134306A5062569126 @default.
- W2980134306 hasAuthorship W2980134306A5069018938 @default.
- W2980134306 hasAuthorship W2980134306A5088718007 @default.
- W2980134306 hasAuthorship W2980134306A5090030145 @default.
- W2980134306 hasBestOaLocation W29801343061 @default.
- W2980134306 hasConcept C111278954 @default.
- W2980134306 hasConcept C141071460 @default.
- W2980134306 hasConcept C142724271 @default.
- W2980134306 hasConcept C168563851 @default.
- W2980134306 hasConcept C1862650 @default.
- W2980134306 hasConcept C204787440 @default.
- W2980134306 hasConcept C27081682 @default.
- W2980134306 hasConcept C2776164576 @default.
- W2980134306 hasConcept C2779286237 @default.
- W2980134306 hasConcept C71924100 @default.
- W2980134306 hasConceptScore W2980134306C111278954 @default.
- W2980134306 hasConceptScore W2980134306C141071460 @default.
- W2980134306 hasConceptScore W2980134306C142724271 @default.
- W2980134306 hasConceptScore W2980134306C168563851 @default.
- W2980134306 hasConceptScore W2980134306C1862650 @default.
- W2980134306 hasConceptScore W2980134306C204787440 @default.
- W2980134306 hasConceptScore W2980134306C27081682 @default.
- W2980134306 hasConceptScore W2980134306C2776164576 @default.
- W2980134306 hasConceptScore W2980134306C2779286237 @default.
- W2980134306 hasConceptScore W2980134306C71924100 @default.
- W2980134306 hasIssue "14" @default.
- W2980134306 hasLocation W29801343061 @default.
- W2980134306 hasLocation W29801343062 @default.
- W2980134306 hasLocation W29801343063 @default.